Meiji Seika Partners With Serum Institute of India to Introduce Japanese Encephalitis Vaccine
Japanese drugmaker Meiji Seika Pharma has established a partnership with the Serum Institute of India (SII) to introduce a Japanese Encephalitis vaccine aimed at children in India. Alongside this immunization initiative, the company intends to expand the operations of its Indian subsidiary, Medreich Pharma, focusing on both domestic supply and international exports.
What Happened
Following a meeting in Tokyo with India’s Commerce and Industry Minister Piyush Goyal, Meiji Seika Pharma’s Chief Operating Officer for the pharma segment, Toshiaki Nagasato, outlined the company’s collaborative roadmap with SII. Under the arrangement, SII is slated to pursue regulatory clearances to deliver the pediatric vaccine in India. The vaccine itself has already been commercialized in the Japanese market through a subsidiary of Meiji Seika.
Technical officials from SII have traveled to Japan to review and assimilate the manufacturing technology. According to Nagasato, the collaboration seeks an accelerated approval timeline, with SII expected to submit applications for domestic marketing authorization in the coming year. Beyond the vaccine initiative, Meiji Seika confirmed plans to invest further in Medreich Pharma, a business it acquired in 2014, to scale up generic drug production and enhance outbound shipments.
Key Highlights
- Vaccine Partnership: Meiji Seika Pharma and SII have partnered to bring a Japanese Encephalitis vaccine for children to the Indian market, building on an initial project milestone achieved last April.
- Regulatory Filings: SII is expected to submit approval applications in India next year to secure clearance for distribution and marketing.
- Cost Efficiency: The initiative leverages Japan’s specialized technology alongside SII’s low-cost manufacturing model to supply the vaccine at an affordable price point.
- Medreich Expansion: Meiji Seika plans undisclosed capital investments into Medreich Pharma to expand generics output within India and support exports to destinations including the United Kingdom, Canada, European markets, and African nations.
- Government Dialogue: The developments were detailed by Meiji Seika leadership after discussions with Union Minister Piyush Goyal in Tokyo.
Why This Matters
According to information from the World Health Organization cited in the development, three types of Japanese Encephalitis vaccines exist for administration to children. The partnership matches Japan’s technical expertise in addressing the disease with India’s scale in affordable pharmaceutical production, creating a pathway to deliver low-cost immunizations for pediatric use.
Additionally, the planned capital injection into Medreich indicates ongoing strategic interest from international pharmaceutical corporations in Indian manufacturing bases to cater to both the domestic market and regulated overseas markets such as the UK, Europe, and Canada.
What to Watch Next
The immediate milestone involves the regulatory timeline. Stakeholders are watching for SII’s formal application for vaccine approval in India, targeted for next year, alongside efforts to secure an accelerated review from authorities. Details regarding the exact financial scope of Meiji Seika’s investment into Medreich Pharma’s generic manufacturing facilities are also anticipated as expansion plans progress.
Frequently Asked Questions
What disease does the SII and Meiji Seika partnership target?
The partnership focuses on bringing a vaccine for Japanese Encephalitis to India specifically for children.
What role will the Serum Institute of India play in this tie-up?
SII will manage the regulatory clearance process in India, leverage its low-cost manufacturing capabilities, and market the pediatric vaccine once approved.
Has this Japanese Encephalitis vaccine been used previously?
Yes, a subsidiary of Meiji Seika Pharma has already marketed this vaccine in the Japanese domestic market.
What are Meiji Seika’s plans for Medreich Pharma?
Meiji Seika intends to invest in Medreich, which it acquired in 2014, to grow generic operations in India and boost exports to regions including the UK, Canada, Europe, and Africa.
Source: Times of India report based on statements by Meiji Seika Pharma COO Toshiaki Nagasato.